– Study will assess the safety, pharmacokinetic and pharmacodynamic profiles and anti-tumor activity for CV6-168 in the treatment of multiple solid cancers, including colon, gastric, breast, ovarian, ...
BELFAST, United Kingdom, Dec. 14, 2023 (GLOBE NEWSWIRE) -- CV6 Therapeutics (‘CV6’), a drug development biotechnology company that specializes in innovative small molecule therapeutics for cancer and ...
Belfast, UK, 2 November 2022 – CV6 Therapeutics (‘CV6’), a drug development biotechnology company that specializes in innovative small molecule therapeutics for cancer and inflammatory diseases, ...
CV6 Therapeutics (NI) Ltd. has secured US$9.2 million to progress its lead oncology asset CV6-168 into a first-in-human phase Ia trial and perform further scientific development work. CV6-168 is a ...
A QUEEN'S University spin-in which has developed a potentially life-saving new cancer treatment is to invest £8 million to take its first anti-cancer drug through a first-in-human clinical trial. CV6 ...
CV6 Therapeutics is developing next-generation cancer treatment, and it is looking backwards to make the future better. Emily McDaid reports. CV6 Therapeutics doesn’t replace traditional chemotherapy; ...
BELFAST, Northern Ireland, Aug. 15, 2024 (GLOBE NEWSWIRE) -- CV6 Therapeutics (NI) Ltd. (“CV6”), a clinical-stage pharmaceutical company dedicated to improving the lives of patients with cancer and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results